Investor Overview

Natera

About Natera

Natera is a rapidly-growing diagnostics company with proprietary bioinformatics and molecular technology for analyzing DNA. Natera’s complex technology has been proven clinically and commercially in the prenatal testing space and the Company is actively researching its applications in the liquid biopsy space for developing products with oncology applications.

Since 2009, Natera has launched seven molecular diagnostic tests, many of which are available through major health plans accounting for more than 140 million covered lives in the United States. The Company’s own robust laboratory processes thousands of genetic tests per month.

Natera’s goal is to transform the way people – both providers and patients – respond to and manage genetic diseases.

Learn More About Natera

Stock Information

Data Provided by Refinitiv. Minimum 15 minutes delayed.

News

Recent News

Natera Files Patent Infringement Suit Against Inivata  -  1/20/2021
SAN CARLOS, Calif. , Jan. 20, 2021 /PRNewswire/ --  Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, filed a lawsuit today against Inivata, Ltd. and its wholly-owned subsidiary Inivata, Inc. for alleged infringement of Natera's U.S. Patent Nos. More »
New Data at the 2021 ASTS Winter Symposium to Showcase Benefit of Serial Prospera™ Testing  -  1/14/2021
SAN CARLOS, Calif. , Jan. 14, 2021 /PRNewswire/ --  Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA (cfDNA) testing, today announced it will present new data on the Prospera test at the American Society of Transplant Surgeons (ASTS) 21st Annual Winter Symposium, taking More »
Natera to Present New Colorectal Cancer Data at the 2021 ASCO GI Symposium  -  1/12/2021
Oral presentation showcases the largest early-stage CRC cohort to date, further validating the serial use of Signatera™ for early recurrence detection and MRD assessment SAN CARLOS, Calif. , Jan. 12, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA More »
Natera to Webcast Live Presentation at the 39th Annual J.P. Morgan Healthcare Conference  -  1/5/2021
SAN CARLOS, Calif. , Jan. 5, 2021 /PRNewswire/ --   Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that it will webcast a live presentation at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 12, 2021 at 12:40 p.m. PT ( 3:40 p.m. More »
U.S. Patent Office Upholds Validity of Natera's Early Priority Date '592 cfDNA Patent  -  12/18/2020
SAN CARLOS, Calif. , Dec. 18, 2020 /PRNewswire/ --  Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA (cfDNA) testing, is pleased that the United States Patent Office granted Natera a significant win when it denied a patentability challenge from a multi-national sequencing More »
Event

Upcoming Events

More events are coming soon.
Events

Past events

Footer disclaimer

Footer disclaimer

© Natera 2021. All Rights Reserved. The tests described on this site were developed by Natera, Inc. a laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). The tests have not been cleared or approved by the U.S. Food and Drug Administration (FDA). Although FDA does not currently clear or approve laboratory-developed tests in the U.S., certification of the laboratory is required under CLIA to ensure the quality and validity of the tests.